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Non-amyloidogenic effects of α2 adrenergic agonists:
implications for brimonidine-mediated neuroprotection
Shereen Nizari1, Li Guo1, Benjamin M Davis1, Eduardo M Normando1,2, Joana Galvao1, Lisa A Turner1, Mukhtar Bizrah1,
Mohammad Dehabadi1, Kailin Tian1 and M Francesca Cordeiro*,1,2
The amyloid beta (Aβ) pathway is strongly implicated in neurodegenerative conditions such as Alzheimer’s disease and more
recently, glaucoma. Here, we identify the α2 adrenergic receptor agonists (α2ARA) used to lower intraocular pressure can prevent
retinal ganglion cell (RGC) death via the non-amyloidogenic Aβ-pathway. Neuroprotective effects were confirmed in vivo and
in vitro in different glaucoma-related models using α2ARAs brimonidine (BMD), clonidine (Clo) and dexmedetomidine. α2ARA
treatment significantly reduced RGC apoptosis in experimental-glaucoma models by 97.7% and 92.8% (BMD, Po0.01) and 98%
and 92.3% (Clo, Po0.01)) at 3 and 8 weeks, respectively. A reduction was seen in an experimental Aβ-induced neurotoxicity model
(67% BMD and 88.6% Clo, both Po0.01, respectively), and in vitro, where α2ARAs significantly (Po0.05) prevented cell death,
under both hypoxic (CoCl2) and stress (UV) conditions. In experimental-glaucoma, BMD induced ninefold and 25-fold and 36-fold
and fourfold reductions in Aβ and amyloid precursor protein (APP) levels at 3 and 8 weeks, respectively, in the RGC layer, with
similar results with Clo, and in vitro with all three α2ARAs. BMD significantly increased soluble APPα (sAPPα) levels at 3 and
8 weeks (2.1 and 1.6-fold) in vivo and in vitrowith the CoCl2 and UV-light insults. Furthermore, treatment of UV-insulted cells with an
sAPPα antibody significantly reduced cell viability compared with BMD-treated control (52%), co-treatment (33%) and untreated
control (27%). Finally, we show that α2ARAs modulate levels of laminin and MMP-9 in RGCs, potentially linked to changes in Aβ
through APP processing. Together, these results provide new evidence that α2ARAs are neuroprotective through their effects on
the Aβ pathway and sAPPα, which to our knowledge, is the first description. Studies have identified the need for α-secretase
activators and sAPPα-mimetics in neurodegeneration; α2ARAs, already clinically available, present a promising therapy, with
applications not only to reducing RGC death in glaucoma but also other neurodegenerative processes involving Aβ.
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Glaucoma is a major cause of visual impairment worldwide
and is characterised by optic neuropathy and visual field loss.
Retinal ganglion cell (RGCs) apoptosis is considered an early
hallmark of glaucoma1 and raised intraocular pressure (IOP) is
presently the only modifiable risk factor.2 As a proportion of
glaucoma patients continue to lose vision despite effective
IOP control,3 IOP-independent risk factors are increasingly
thought to have a role in glaucoma pathology.
Amyloid beta (Aβ), the major constituent of senile plaques in
Alzheimer’s disease (AD), has recently been implicated in
glaucoma pathology.4,5 Aβ is associated with abnormal
processing of amyloid precursor protein (APP). APP can be
cleaved either by α-secretase via the non-amyloidogenic
pathway, producing soluble APPα (sAPPα), or β-secretase
producing sAPPβ, and Aβ, via the amyloidogenic pathway.6
Using rodent glaucoma models, the amyloidogenic pathway
has recently been identified as a target for the development of
novel neuroprotective glaucoma therapies.4,5 Here, Aβ
deposition was found to induce RGC apoptosis, a finding
supported by a study on glaucoma patients reporting reduced
Aβ concentrations in the vitreous.7 Aβ may therefore be
important in the stress–response to glaucomatous neurode-
generation and offers a novel therapeutic target.4
Brimonidine (BMD), Clonidine (Clo) and Dexmedetomidine
(Dex) are α2 adrenergic receptor agonists (α2ARAs).
Apraclonidine, a para-amino derivative of Clo, is a topical α
2ARA8 routinely used in the clinic to reduce IOP spikes
induced by neodymium:YAG laser treatment for posterior
capsule scarring after cataract surgery.9 However, the
reduced activity of Apraclonidine in controlling IOP with
chronic usage10 coupled with increased risk of follicular
conjunctivitis,11 renders it unsuitable for long-term glaucoma
management. BMDwas introduced as an IOP-lowering agent;
however, increasing experimental evidence suggests it also
has IOP-independent neuroprotective activity.12 This was
clinically demonstrated in a prospective, randomised-
controlled study where BMD was reported to significantly
preserve visual field in low-tension glaucoma patients
compared with the beta-blocker timolol.13 Both Clo and Dex
are used as anaesthetics,14 Clo is used to treat migraine,
hypertension and menopausal flushing,15 and Dex for seda-
tion during intensive care.16 In vivo studies have demonstrated
Clo and BMD to have retinal neuroprotection17–19 with
functional benefits,20,21 and Dex to have neuroprotection
against cerebral ischaemia,22 excitotoxicity23 as well as in a
model of traumatic brain injury.24
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Although α2AA and α2AB receptors have been identified in
the RGC layer (RGCL) of the inner retina,25 the mechanisms
by which α2A agonists exert neuroprotection are not well-
established. Various pathways have been proposed, including
cyclic adenosine monophosphate (cAMP) reduction,26 NMDA
receptor neuromodulation,21 increasing cell survival proteins
p-Akt and bcl-2 (ref. 27) and neurotrophic factor expression.22
The present study seeks to delineate the mechanisms of
α2A-mediated neuroprotection using glaucoma-related in vivo
and in vitro models, and investigate the involvement of the
Aβ-pathway.
Results
α2ARAs are neuroprotective against retinal neuronal
death in vitro and in vivo. Retinal neuronal cells (RNs)
were pre-treated for 24 h with BMD, Dex or Clo before
insulting with the hypoxia-mimic cobalt chloride (CoCl2)
28 or
UV light to induce neurotoxicity, based on previously
determined IC50 doses.
29 CoCl2 induced a decrease in cell
viability in both primary and immortalised cell types, which
was significantly reduced with BMD at all concentrations
assessed (0.1–100 μM, Po0.01 Figures 1a and c), whereas
Clo was protective at 0.1, 1 and 100 μM (Po0.05), whereas
Dex was effective at 0.01 μM (Po0.001, Figure 1a).
BMD significantly increased cell viability of UV-insulted cells
at 10 and 100 μM (Po0.001, Figure 1b). Clo and Dex were
neuroprotective at 0.01 μM (Po0.001 and Po0.001, respec-
tively, Figure 1b). BMD reduced UV-induced RN death in a
dose-dependent manner with an IC50 value of 64±14 μM. At a
peak activity of 1 mM, BMD significantly increased cell viability
against UV insult (76.1% compared with 32.2%, respectively,
Po0.001, Figure 1d).
Effects of systemic α2A agonists BMD and Clo were
examined in vivo using an ocular-hypertensive (OHT) rat
model.30 Comparison of the IOP profile between untreated
OHT control and no-OHT groups showed OHT surgery
produced a significant increase in IOP up to 3 weeks post
surgery (Po0.05, Figure 2a). Systemic Clo treatment lowered
IOP at 1, 2 and 3 weeks compared with the untreated OHT
group (all Po0.01), whereas systemic BMD had no effect on
IOP (Figure 2a), as expected.31
Significantly, more apoptotic RGCs were observed at 3 and
8 weeks in the untreated OHT model compared with the no-
OHT control eyes (Po0.01; Figure 2b), with peak RGC
apoptosis occurring at 3 weeks, consistent with previous
findings.1,4 Both BMD and Clo significantly reduced RGC
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Figure 1 α2 agonists are neuroprotective against RGC death in vitro. α2 agonists’ effects on neuroprotection were investigated in vitro using the MTTassay in immortalised
RNs against CoCl2 (hypoxic) and UV (stress) insults; against 250 μM CoCl2 BMD showed significant neuroprotection at all concentrations tested, Dex showed protection at
0.01 μM and Clo was neuroprotective at 0.1, 1 and 100 μM (a). Against the insult of UV, BMD was protective at 100 and 10 μM and Clo and Dex were both protective at 0.01 μM
(b). The protective effects of BMD at 10 and 100 μM against CoCl2 were reproduced in mouse-derived primary mixed retinal cultures (c). In immortalised RNs, BMD (10 μM) was
found to be protective against an UV-light insult of 80 j/cm2 (d). All experiments were carried out in triplicate. All means± S.E.M.; * Po0.05, **Po0.01, ***Po0.001
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apoptosis compared with untreated controls at 3 weeks, by
97.7% and 98%, respectively (Po0.001), and at 8 weeks
(92.8% and 92.3%, Po0.01), as shown in Figures 2b–e. No
significant difference was observed between 3 and 8 weeks
BMD and Clo-treated groups (P40.05, Figures 2b–e). BMD’s
anti-apoptotic effect was found to coincide with increased
levels of the cell survival protein P-Bad both in vivo and ex vivo
(Supplementary data). In summary, these experiments
demonstrate that α2ARA reduce levels of RGC apoptosis
and cell death both in vivo and in vitro.
The neuroprotective effect of α2ARAs is associated with
modulation of Aβ in RNs in vitro and in vivo. Previous
studies suggest that glaucoma-related RGC apoptosis
involved Aβ, and its therapeutic targeting was
neuroprotective.4 The interaction of α2ARAs BMD, Dex and
Clo with RN-associated Aβ was investigated in vitro with
CoCl2 and UV-associated cell toxicity using immunocyto-
chemistry. Both CoCl2 and UV significantly increased Aβ
levels (Po0.001, Figure 3a) by 1.5- and 2.2-fold, respectively.
Treatment with α2ARA on CoCl2 insulted cells significantly
decreased Aβ detected when co-treated with 10 and 100 μM
BMD (Po0.01 and Po0.001, respectively), with a dose-
dependent reduction in Aβ levels observed (20%(1 μM),
34.7%(10 μM) and 56.8%(100 μM), Figures 3b–d). At the
same concentrations, Clo and Dex treatments were asso-
ciated with reductions in Aβ staining of; Clo: 0.3, 21.4, 23.4%
and Dex: 4, 33.5 and 30.8%, respectively. In all, 10 and
100 μM BMD treatment also significantly reduced APP
detected, by 35.4 and 26.8% (Figures 3e–g; Po0.05). BMD
treatment was more effective with lower concentrations on
UV-induced Aβ, with 60.5, 64.5 and 81.4% decreases at
0.1 μM, 1 μM and 10 μM, respectively (Po0.001, Figure 3h).
Consistent with previous in vivo findings,4 elevated levels of
Aβ were observed in the RGCL 3 weeks post OHT model
induction compared with no-OHT control (Po0.001,
Figure 4a) associated with a significant increase in APP
(Po0.001, Figure 4b).
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Figure 2 α2 agonists are neuroprotective against RGC death in vivo. (a) Rats had IOP surgically elevated in one eye (OHTos) in an established model of ocular hypertension
(OHT). IOP was significantly increased in untreated control (n= 10) and systemic BMD-treated groups (n= 10) compared with no-OHT (contralateral eyes), up to 3 weeks after
surgery. In comparison, systemic Clo treatment significantly reduced IOP (n= 10). (b) α2A agonist treatment (BMD, Clo) significantly decreased RGC apoptosis compared with
untreated controls at 3 (43-fold and 50-fold reduction for BMD and Clo, respectively) and 8 (14-fold and 13-fold reduction for BMD and Clo, respectively) weeks after surgery. (c–e)
Representative DARC images showing the in vivo retinal image of an untreated OHT (c) compared with BMD (d) and Clo-treated (e) rats at 3 weeks after IOP elevation. Each
white spot represents an individual retinal ganglion cell undergoing apoptosis that is positive for fluorescently labelled annexin A5. (a) and (b) show means± S.E.M.; **Po0.01,
***Po0.001
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Treatment of the OHT model with α2ARAs significantly
reduced Aβ detected in the RGCL 3 weeks post IOP elevation
(Figures 4a and c-e). BMD treatment was associated with a
ninefold (3 weeks) and 25-fold (8 weeks) reduction in Aβ
levels, whereas Clo induced a 3.4-fold (3 weeks) decrease
(Po0.01 and Po0.05, respectively). A similar reduction in
APP was observed in the RGCL with BMD treatment
associated with a 36- (3 weeks) and a fourfold (8 weeks)
reduction, and Clo an eightfold (3 weeks) and fourfold
(8 weeks) reduction(Po0.01 in each case, Figures 4b–e).
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Figure 3 α2A agonists directly reduce retinal neuronal Aβ and APP levels in different in vitrostress models. α2 agonists’ ability to reduce Aβ levels was next investigated
in vitro in immortalised RNs using CoCl2 and UV insults, which significantly increased Aβ levels (a). Aβ levels were significantly reduced in CoCl2 samples when co-treated with 10
and 100 μM BMD (b). All α2A treatments were associated with a reduction in Aβ levels at concentrations of 10 and 100 μM, although BMD was found to be most effective.
Representative images from CoCl2 insulted cells show BMD treatment (c) reduced Aβ (red) staining in RNs compared with CoCl2 only treatment (d); (α-tubulin staining (green),
DAPI staining (blue)). APP levels were significantly reduced with 10 μM BMD treatment against CoCl2 insult (e). Representative images from CoCl2 insulted RGCs show BMD
treatment (f); reduced APP (green) staining in RGCs compared with CoCl2 only treatment (g); (DAPI staining (blue)). (h) Staining for Aβ induced by UV insult revealed a significant
decrease in levels with treatment of 0.1, 1 and 10 μM BMD. Experiments were carried out in triplicate. All data; means± S.E.M.; * Po0.05, **Po0.01, ***Po0.001
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Furthermore, APPandAβ showed greater colocalisation in the
RGCL of the untreated OHT model (Figure 4c) compared with
α2ARA-treated OHT model (Figures 4d and e); at 3 weeks
(Po0.001 and Po0.01, BMD and Clo, respectively) and
8 weeks (Po0.001 BMD, Figure 4f). Although the Pearson’s
coefficient values are not significantly different in the OHTand
the no-OHT controls, in the OHT controls there is a decreased
Aβ (Figure 4a) and APP (Figure 4b) levels, as demonstrated by
the ratio between the Aβ intensity and Pearson’s coefficient
value to in the no-OHT group being 5.10 comparedwith 28.6 in
the OHT model at 3 weeks, and 8.87 at 8 weeks (Figures 4a
and b). This change in colocalisation observed with α2ARA
treatment is suggestive of altered processing of APP favouring
the non-amyloidogenic pathway (Figure 4f), which is markedly
different to the untreated no-OHT control, where less Aβ and
APPwas detected compared with the OHTmodel (Figures 4a,
b and f).
To further investigate whether α2ARA therapy acted via an
Aβ-dependent pathway, α2ARAs were administered into a
previously characterised in vivo Aβ-induced RGC apoptosis
model.4 BMD and Clo treatment significantly reduced RGC
apoptosis in response to intravitreal administration Aβ25–35
(25 nM), compared with Aβ25–35 only controls (Figures 4g–j).
RGC apoptosis was reduced by 67% (BMD, Po0.01) and
88.6% (Clo, Po0.01), respectively, suggesting a direct effect
of α2ARAs on Aβ-induced RGC apoptosis.
α2A agonists directly affect the non-amyloidogenic
pathway and elicit neuroprotective activity through
sAPPα. Having established α2ARA treatments reduce
Aβ-associated-RGC apoptosis, we investigated whether
these effects were mediated through changes to APP
processing. Levels of sAPPα (a product of the non-
amyloidogenic pathway6) were histologically assessed in
the OHT model. sAPPα staining was not significantly different
either at 3 or 8 weeks in the RGCL in untreated OHT and
control eyes (Figure 5a). BMD treatment significantly
increased sAPPα levels at both 3 and 8 weeks (2.1- and
1.6-fold increase, respectively) compared with untreated OHT
controls (Po0.05 and Po0.01, Figures 5a–e). Clo treatment
had no effect.
The effect of BMD on the non-amyloidogenic pathway was
confirmed in vitro using the hypoxia mimetic CoCl2 to induce
RN toxicity. A twofold significant increase in sAPPα levels was
observed in response to 10 μM and 100 μM BMD treatment
(Po0.01, Po0.05, respectively, Figures 5f–h).
Having previously established BMD treatment reduces Aβ
levels in response to UV light induced toxicity, the effect of an
sAPPα antibody on UV-insulted and BMD-treated cells was
investigated. Although sAPPα antibody exposure caused no
significant change in RGC viability after UV exposure, it
significantly inhibited protection by BMD therapy (Figure 5i).
This observation, coupled with data demonstrating that
α2ARA treatment significantly reduced APP levels, suggests
α2ARA mediated RGC neuroprotection is achieved through
increased sAPPα through upregulation of non-amyloidogenic
APP processing.
The neuroprotective effect of α2ARAs via Aβ-related
pathways involves modulation of the ECM. Laminin and
MMP-9 expression have been implicated in Aβ-related
pathways.32 The occurrence of RGC apoptosis in OHT is
associated with a reduction in laminin in the RGCL at
3 months in the same OHT model.33 We therefore investi-
gated whether extracellular matrix (ECM) modulation had a
role in α2ARAs-mediated neuroprotection using the
OHT model.
A twofold reduction in laminin was observed in the RGCL at
3 and 8 weeks post OHT induction compared with the no-OHT
control eyes (Po0.05, Figure 6a). BMD treatment restored
laminin levels in the OHT model RGCL at both 3 and 8 weeks
(Po0.05, Figures 6a–e). A significant (Po0.05) twofold
reduction in MMP-9 expression was observed in the RGCL
3 weeks post OHT induction but not at 8 weeks (Figures 6f–j).
BMD treatment induced a marked but not statistically
significant increase in MMP-9 levels at 8 weeks (Figure 6f).
Laminin and MMP-9 expression was also investigated in the
Aβ-inducing apoptosis model.4 BMD treatment was asso-
ciated with a significant reduction in laminin deposition in the
RGCL versus Aβ-treated controls, although there were no
differences in comparison to the no-OHT control (unpaired
t-test, Po0.05, Figure 6k).
To further investigate the effect of α2ARAs on MMP-9
expression, in vitro studies were performed on RNs insulted
with CoCl2. Using zymography, CoCl2 increased both pro- and
active MMP-9 (Figure 6h, lane 2), compared with untreated
cells (lane 1). Treatment with BMD reduced both pro- and
active MMP-9 (Figure 6l). A marked but not statistically
significant reduction in MMP-9 was observed histologically in
the in vivo Aβ-induced apoptosis model, although in the
Aβ-treated eyes, the MMP-9 staining was significantly lower
than in the no-OHT controls (Po0.001, Figure 6m). These
results suggest that α2ARA modulate laminin and MMP-9
expression in RGCs, which may be linked to changes in
Aβ and APP processing.
Discussion
The present study confirms the neuroprotective actions of
α2ARAs using in vivo and in vitro models of retinal
neurodegeneration with a novel IOP-independent mechanism
of action. This mechanism proposes that a reduction in RGC
apoptosis is achieved through reduced Aβ production, and its
precursor APP, via stimulation of the non-amyloidogenic
pathway as evidenced by a significant increase in sAPPα,
which leads to modification of ECM proteins laminin and
MMP-9 (Figure 7).
Compared with Clo, systemic BMD administration does not
affect IOP,31,34 suggesting that BMD’s neuroprotective effect is
IOP independent. This observation is supported by the LoGTs
study,13 where BMD was effective in preserving visual field
independent of IOP reduction in adults with low-pressure
glaucoma. Further investigations of the clinical use of BMD as
a neuroprotectant are currently underway (clinicaltrials.gov
NCT00658619, NCT00693485, NCT01229410). Further-
more, the ability of BMD to improve visual function is
documented in rodent models of retinal disease.35–37
This study suggests that different activity levels between
α2ARAs could be attributed to differences in their selectivity for
the α2A and the α2AA subtype. BMDandDex are direct agonists
α2 agonist neuroprotection against amyloid β
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of the α2AA receptor subtype, and are inhibited by the α2AA
antagonist yohimbine in vivo27 and in vitro.38 In comparison,
Clo has reduced selectivity for α2 receptors.8,17,39
Neuroprotective effects α2ARAs are understood to be
primarily mediated though α2A receptors,11 supporting BMD’s
effects in this study. α2A receptors are G-protein-coupled-
receptors whose activation leads to an inhibition of adenylate
cyclase and a decrease in cAMP.40 cAMP is implicated in
Aβ modulation by stimulation of APP synthesis and proces-
sing, affecting the amyloidogenic and non-amyloidogenic
pathways,41,42 potentially through the cAMP/PKA/APP/Aβ
pathway.43
Several mechanisms have been proposed for α2A-
mediated neuroprotection, including increased expression of
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Figure 5 α2A agonists directly affect the non-amyloidogenic pathway and are neuroprotective through sAPPα. (a) Treatment with the α2A receptor agonist BMD significantly
increased sAPPα levels at both 3 (2.1-fold) and 8 weeks (1.6-fold) compared with untreated control in the OHT model. (b–e) Representative retinal histological images of sAPPα
(red) and nuclei (DAPI, labelled blue) of the RGCL of a 3 weeks (b, c) and 8 weeks. (d, e) OHT model in the absence (b, d) and presence (c, e) of BMD treatment, showing
increased sAPPα staining with BMD. (f–h) sAPPα levels were significantly increased in vitro in the CoCl2 model with 10 and 100 μM BMD treatment compared with control (h).
Representative images from BMD and CoCl2 treated cells (g), and CoCl2 only treated cells (f) stained for sAPPα (red), α tubulin (green), DAPI (blue), show significantly increased
sAPPα staining with BMD treatment. (i) sAPPα activity was next assessed using UV light to induce RGC death; the sAPPα antibody treatment significantly inhibited the
neuroprotective effects of BMD against UV, suggesting that BMD is neuroprotective through sAPPα, promoting APP processing through the non-amyloidenic pathway. in vitro
experiments were carried out in triplicate. Data are means±S.E.M. *Po0.05, **Po0.01, ***Po0.001
Figure 4 The neuroprotective effect of α2A receptor agonists is associated with modulation of Aβ in vivo. (a) Immunohistochemistry revealed a significant increase in Aβ in
OHTeyes compared with the no-OHT control at 3 weeks post IOP elevation. BMD and Clo treatment significantly reversed this effect (BMD; ninefold decrease at 3 weeks and
25-fold decrease at 8 weeks, Clo; a 3.4-fold decrease at 3 weeks). (b) APP concentrations were similarly increased at 3 weeks in comparison with the no-OHT control. BMD and
Clo treatment significantly reversed this effect with a 36-fold (BMD) and eightfold (Clo) reduction in APP levels in the RGCL at 3 weeks, and a fourfold reduction (BMD and Clo) at
8 weeks. Representative images of Aβ (red), APP (green) and nuclei (DAPI, blue) labelled RGCL of a 3 weeks OHT model in the absence (c) and presence of BMD (d) and Clo
treatment (e), showing increased Aβ and APP colocalisation (highlighted by red arrows) in the untreated OHT compared with α2A agonist treated eyes (d, e). (f) α2A agonist
treatment significantly decreased colocalisation of Aβ and APP detected at both 3 (BMD and Clo) and 8 weeks (BMD) compared with untreated OHTeyes. (g) Assessment of Aβ
neurotoxicity was performed following intravitreal injection of Aβ25–35 in vivo. Both BMD and Clo significantly reduced levels of RGC apoptosis as detected using AlexaFluor
488 labelled annexin A5 to label apoptosing RGCs. (h) Representative in vivo image of α2A agonist treated Aβ model and histologically ex vivo (i), demonstrating a
reduction in annexin labelled RGCs compared with untreated Aβ model (j). In vitro experiments were carried out in triplicate. All data; means± S.E.M. * Po0.05, **Po0.01,
***Po0.001
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Figure 6 The neuroprotective effect of α2A agonist via Aβ-related pathways involves modulation of the extracellular matrix. (a) OHT surgery induced a significant reduction in
laminin levels in the RGCL at 3 weeks compared with the no-OHT control. BMD treatment significantly increased levels of laminin at 3 (2.2-fold) and 8 weeks (2.9-fold) in
comparison with the respective controls. (b–e) Representative images show low levels of laminin (red) in the RGCL of a 3 (b) and 8 (d) weeks OHTeye, compared with the same
time points in BMD-treated OHTeyes (c, e), (DAPI, blue). (f) MMP-9 levels in the RGCL were significantly lower at 3 weeks in OHTeyes compared with the no-OHT control. (g–j)
Representative images show the marked but non-significant increase in general (pro and active forms) MMP-9 levels (green) in the RGCL of BMD-treated OHT models at 3 (h)
and 8 (j) weeks compared with OHT control eyes (g, i), (DAPI, blue). (k) In comparison, a different pattern was seen in the Aβ neurotoxicity model, where BMD treatment was
associated with a significant reduction in laminin in the RGCL. (l) Further assessment of MMP-9 activity was performed using zymography on immortalised RN exposed to CoCl2,
where BMD treatment appeared to substantially reduce MMP-9 activity in both pro- and active forms, although this effect was reduced at a high concentration (100 μM). (m) BMD
treatment did not significantly alter levels of MMP-9 in the RGCL of the Aβ apoptosis-inducing model, although levels were significantly different from no-OHT control. in vitro
experiments were carried out in triplicate. Error bars±S.E.M. *Po0.05, **Po0.01, ***Po0.001
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neurotrophic factors.17,22,27,44–46 Other survival pathways
include P-Akt, bcl-2 and extracellular signal-regulated kinase
(ERK),27,47 which support this study’s observed increase in
P-Bad(Ser136). α2A agonists have also been reported to
effect the glutamate pathway,48 with reductions in intracellular
cAMP production and cytosolic calcium shown in RGCs.21
Recently, BMD was reported to reduce expression of NMDA
subunits NR1 and NR2A in a model of ischaemia.19 Similar
activity in excitotoxicity models is reported for Clo17,49 and
Dex50 in the CNS.
Elevated APP and Aβ have been reported in glaucoma
models,4,51 potentially linking elevated IOP promotion of APP
processing, and inhibition of APP anterograde transport from
the RGCL to the optic nerve.51,52 BMD is reported to preserve
optic nerve axons and active transport throughout the visual
pathway in a rodent OHT model,18 which may explain the
present study’s finding where α2A agonists reduced levels of
APPand Aβ in the RCGL of the OHTmodel. This hypothesis is
supported by our in vitro data, where CoCl2 and UV-induced
elevation of APP and Aβ was inhibited by α2ARAs. A possible
pathway by which this may occur is through α2ARAs’ ability to
inhibit cAMP production.21
This study suggests for the first time that the neuroprotective
effects of α2ARA BMD are directly associated with increased
sAPPα, as the observed BMD-mediated neuroprotective
effect was reversed using an sAPPα antibody in vitro.
Furthermore, the increase in sAPPα appears to be specific
to α2AA activity, as Clo did not produce a comparable effect.
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Previously, sAPPα was reported to be neuroprotective
in vitro.53,29 More recently, Obregon et al. reported that sAPPα
decreases Aβ generation directly by associating with the β-site
APP-converting enzyme (BACE1) both in vivo and in vitro.
Importantly, the authors proposed that the levels of sAPPα
were so crucial that an imbalance could stimulate amyloido-
genic APP processing,54 concluding that sAPPαmimetics are
a potential therapeutic target for the treatment of AD. This was
further highlighted in a recent paper by Willem where
unwanted side-effects on neuronal activity were implicated
by treatment with BACE1.55 The results of the present study
suggest that α2AA agonists are sAPPαmodulators, promoting
RGC survival in a non-IOP-dependent manner.
A mechanism for the stimulation of sAPPα by α2A agonists
may be through the activation of α-secretases, which can
occur via protein kinase C (PKC), phosphatidylinositol 3-
kinase (PI3K) and mitogen-activated protein kinase–ERK.56
Evidence suggests that APP cleavage by the α-secretase
ADAM10 (a disintegrin and metalloproteinase and physiolo-
gical α-secretase in neurons) constitutively produces sAPPα
through 5-HT4 receptors in a cAMP-independent pathway.
When stimulated by 5-HT4 receptors agonists, however,
sAPPα secretion is mediated through cAMP/Epac (exchange
protein activated by cAMP) signalling.57 A possible explana-
tion for this study’s findings is that α2ARAs could directly
activate α-secretase ADAM10 and sAPPα production through
cAMP/Epac modulation.
ADAM10 and MMP-9 have been reported to stimulate
sAPPα production and decrease Aβ, through α-secretase-like
activity.58,59 We present in vitro data suggesting that α2ARAs
increase levels of pro-MMP-9 and sAPPα, whereas decreas-
ing Aβ levels. This concurs with in vivo studies where elevated
MMP-9 levels in a AβPP transgenic mouse model led to a
reduced plaque burden and increased sAPPα levels.60 As
both ADAM10 and MMP-9 are matrix metalloproteases, their
activity levels may be similar.61,62 In the retina, NMDA
activation is reported to increase MMP-9 activity;63 α2A
agonists could therefore reduce MMP-9 activity by inhibiting
retinal excitotoxicity.21 Furthermore, MMP-9 is reported to be
influenced by Aβ, as intracerebroventricularly injected Aβ is
reported to increase MMP-9 levels in vivo.63 The reduction in
Aβ levels by α2ARAs observed may be responsible for the
reported reduction in active MMP-9 levels. The effects of
α2ARAs on MMP-9 appear complex and closely related: α2A
agonists may reduce active MMP-9 levels through modulation
of NMDA and Aβ activity, but this reduction in MMP-9 may in-
turn decrease its α-secretase-like activity and the subsequent
promotion of the non-amyloidogenic pathway.
MMP-9 activity in retinal neurodegeneration is linked with
laminin, it was reported that RGC degeneration is associated
with reduced laminin and stimulation of MMP-9.33 We report
similar changes in laminin in the RGCL of the OHT model, but
at earlier time points than previously described. Laminin is
suggested to be neuroprotective through a laminin-integrin
signalling pathway, with evidence that laminin promotes RGC
survival in vitro through β1 integrin-focal adhesion kinase
signalling.64 The reduction in laminin reported in this study
was reversed by α2A agonist BMD treatment. BMD has been
reported to induce laminin binding protein expression, laminin-
induced neuronal and axonal changes, essential for promoting
axonal preservation and growth.65
Furthermore, laminin is linked tomodification of APPand Aβ
processing and found in senile plaques in Alzheimer’s
Disease,66 where it prevents Aβ fibril formation and reduces
neurotoxicity.32 This effect was confirmed in vivo, with laminin
Amyloidgenic
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sAPPα
APP
Cell Death
LBP
GLU
MMP-9
Laminin
P-BAD
Cell Survival
Bad
A2 Agonists
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Non- Amyloidgenic
Figure 7 Diagram representing α2A agonists’ neuroprotective effect against Aβ
toxicity. APP can be processed into Aβ or sAPPα through the amyloidogenic and non-
amyloidogenic pathways, respectively. α2A receptor agonists can negatively affect
the amyloidogenic pathway, preventing cell death, partly by modulating excitotoxicity
caused by glutamate (GLU). α2A receptor agonists can also affect APP processing
via the extracellular matrix, by modulating MMP-9 and laminin through LBP,
preventing further toxic interactions with Aβ and by increasing processing of APP into
sAPPα, promoting the non-amyloidogenic pathway. α2A receptor agonists can also
increase levels of P-Bad, and therefore overall act to promote cell survival and
neuroprotection
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depletion accelerating Aβ-induced neurotoxicity, altering the
distribution of Aβ aggregates in Caenorhabditis elegans.67
Intravitreal injection of Aβ25–35 was found to induce increased
laminin in the RGCL, which was reversed by BMD treatment,
contradictory to the effect of BMD treatment observed in the
OHT model. The increase in laminin observed in the Aβ25–35
model may be a response to direct Aβ-induced
neurotoxicity.32,67 The reduction of Aβ-induced neurotoxicity
with BMD treatment may result in an attenuation of the
increased laminin levels in response to the acute presence of
Aβ. This hypothesis is supported by the observation that BMD
reduces levels of Aβ deposition in both theOHTandAβmodels
in vivo, inhibiting Aβ neurotoxicity and RGC apoptosis.
In addition to modulating Aβ levels through sAPPα, this
study confirms that α2A agonist BMD can elicit neuroprotec-
tion through P-Bad (Ser136) (Supplementary Figure1a–d). Aβ
is reported to increase Bad de-phosphorylation and cell death
by stimulating calmodulin–calcineurin activity.68 BMD-
mediated reduction of Aβ may increase P-Bad, promoting cell
survival pathways involving PI3K, known to be upregulated by
BMD upstream of P-Bad.27 PI3K activity can itself decrease
Aβ levels,69 providing further corroboration that BMD reduces
Aβ. In addition, upstream of Bad, PKC activation simulta-
neously increases sAPPα and reduces Aβ levels, providing
further support for non-amyloidogenic promotion of cell
survival.70
An alternative and complementary pathway by which α2A
agonists reduce Aβ expression in OHT, may be via oxidative
stress modulation.26 Oxidative stress reduces expression of
sAPPα and α-secretase activity71 and is implicated in the
pathogenesis of glaucoma, where an ischaemic element is
well-recognised.72 The observation that BMD increases
sAPPα and reduces Aβ levels in RGCs when exposed to a
hypoxic insult (CoCl2) supports evidence for α2A agonist’s
neuroprotective activity under oxidative stress. Although
Aβ1-42 monomers may possess neuroprotective function,
6
Aβ oligomers and Aβ25–35 used in this study are widely
reported to induce oxidative stress.4 The effects of α2A
agonists against oxidative stress are supported by our
observation that BMD and Clo are protective against
Aβ25–35-induced RGC apoptosis in vivo.
Aβ neurotoxicity is associated with glutamate NMDA
receptor activation and is the basis of the FDA-approved
NMDA receptor antagonist Memantine for the treatment of
Alzheimer’sDisease.73 This pathway has also been implicated
in the development of Aβ induced-dendritic spine loss and tau-
associated neurodegeneration.74 Short-term NMDA receptor
stimulation is reported to increase non-amyloidogenic
α-secretase-mediated APP processing and sAPPα
production,75 whereas chronic stimulation is reported to have
the opposite effect.76 α2ARAs can also modulate NMDA
receptors; Dong et al. report that BMD acts post-synaptically
on NMDA receptors by reducing levels of intracellular cAMP;
this indirect effect could also be responsible for BMD
suppressing Aβ-induced excitotoxicity.21 Clo has been shown
to regulate GABAergic synaptic inputs in theCNS,which could
explain its neuroprotective effect reported in this study in the
OHT model.49
In conclusion, we confirm that α2ARAs are neuroprotective
of RGC death in vivo and in vitro, substantiating previous
reports that this effect is non-IOP dependent. We suggest a
new mechanism by which this occurs; we show through
multiple modalities that α2ARAs modulate Aβ toxicity,
decreasing levels of Aβ and APP in vivo and in vitro, and
increasing sAPPα formation through the non-amyloidogenic
pathway (Figure 7). We specifically demonstrate that neuro-
protective effects of α2ARA BMD are mediated through
sAPPα. Furthermore, BMD affects laminin, in association with
Aβ, which influences RGC survival. Recent studies have
identified the need for α-secretase activators and sAPPα-
mimetics in neurodegeneration. We propose that α2ARAs
may be the most commonly available clinical sAPPα mod-
ulators, and being 'tried and tested' may offer an economical
advantage as a pre-existing therapeutic for neuroprotection.
The applications of α2ARAs may therefore not be limited to
reducing RGC death in glaucoma but also to any neurode-
generative process where Aβ neurotoxicity is involved, such
as AD. This work strongly advocates investigation of the
therapeutic potential of α2ARAs in these disorders.
Materials and Methods
Ethics statement. All procedures were approved by the UK Home Office and
the University College London Ethics Committee and were conducted in accordance
with the Association for Research in Vision and Ophthalmology statement and
ARRIVE guidelines.
Animals. Adult male Dark Agouti rats (200–250 g) (n= 50) were maintained in a
12-hour light/12-hour dark cycle, and provided standard food and water ad libitum.
Animals were anaesthetised by intraperitoneal administration of ketamine (37.5%)
(Ketaset; Fort Dodge Animal Health) and medetomidine (25%) (Dormitor; Pfizer,
Exton, PA, USA) at 2 ml/kg, except for IOP measurements, for which animals were
anaesthetised by 0.4% isoflurane in oxygen.
Chemicals. BMD was purchased from Sigma Aldrich (Dorset, UK), or obtained
from Allergan (Oregon, USA); Clo and Dex were purchased from Santa Cruz
Biotechnology Inc (Santa Cruz, CA, USA).
Rat model of OHT. The OHT model was surgically induced in 30 rats using a
well-established method.30 IOP was elevated in the left eye of each animal by
injection of 50 μl hypertonic saline (1.80 M) into the episcleral veins using a syringe
pump (UMP2, World Precision Instruments, Sarasota, FL, USA). A propylene ring,
with a 1 mm gap cut out of its circumference, was placed around the equator to
prevent saline outflow from other aqueous veins, as described previously.4,33
Contralateral, un-operated eyes served as controls. The IOP of both eyes was
measured in mmHg at regular intervals using a Tonolab Tonometer (Tiolat Oy,
Heisinki, Finland). Treatments of BMD (n= 10), Clo (n= 10) and PBS control
(n= 10) were administered intraperitoneally at the time of surgery. Animals were
imaged for RGC apoptosis by administrating Alexa-488-labelled annexin A5
(1.25 μg in 5 μl) intravitreally at 3 (n= 15) and 8 (n= 15) weeks, before being killed
for histological assessment.1,33 The ratio of IOP was calculated by dividing the IOP
from the operated, OHT left eye (OS) by that of the un-operated, no-OHT right eye
(OD). Analysts were masked to treatment group identity. Statistical analysis on IOP
data was carried out using the non-parametric two-tailed Mann–Whitney test
comparing treated OHT to untreated no-OHT control (n= 5).
Rat model of Aβ. The Aβ model was prepared in 15 rats to induce RGC
apoptosis as described previously.4 In brief, 25nmol Aβ25–35 (Sigma Aldrich) was
dissolved in sterile water and intravitreally administered unilaterally. BMD (n= 5) Clo
(n= 5) or vehicle (PBS) (n= 5) was administered intraperitoneally at the time of Aβ
administration. Rats were imaged for RGC apoptosis (as described above) at
baseline and 3 days following treatments before sacrifice.
Histology and immunohistochemistry. RGC apoptosis counts were
performed in vivo and histologically ex vivo, using whole-retina mounts.4 For whole-
retina mounts, eyes were enucleated and immediately fixed in 4%
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paraformaldehyde following termination. Eyes were dissected at the equator, and
the cornea, lens and vitreous were removed. RGC apoptosis was identified by
fluorescent annexin A5 staining. RGC apoptosis density counts were performed in a
masked fashion by three observers, and were calculated as previously
described.4,77
Immunohistochemistry was performed using antibodies listed in Table 1. Dissected
eyes were fixed in 10% formalin before processing in methanol solutions with
increasing concentrations, and embedding in paraffin.33 In total, 3 μm thick sections
were then cut and incubated with antibodies diluted in TBTA (Table 1). Stained
sections were analysed using fluorescent microscopy (Zeiss Axiovert S100) at x20
magnification, by a masked observer. The RGCL was segmented using a box of fixed
proportions and image background noise was subtracted using a 25 pixel rolling ball
radius, before recording the mean fluorescence intensity through the pixels’ grey
values using ImageJ software (NIH) as previously described.78 Colocalisation
analysis was carried out using the Pearson’s Coefficient test with the ImageJ JaCoP
plugin79 on segmented double-labelled RGCL images.
Cell culture. Both primary murine retinal mixed neuronal cultures and an
immortalised retinal neuronal (RN) cell line (a gift from Dr. Neeraj Agarwal,
Department of Cell Biology and Genetics, UNT Health Science Centre, Fort Worth,
TX, USA) were used. The immortalised line expresses retinal neuronal proteins
Thy-1, Brn-3a and β3 tubulin80 and strong similarity to the 661w photoreceptor cell
line.81 Immortalised cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM; Sigma, Gillingham, UK), supplemented with 10% heat-inactivated fetal
bovine serum (Life Technologies, Paisley, UK), 100 μg/ml penicillin and 100 mg/ml
streptomycin (Life Technologies). Primary murine (C57BL/6) mixed retinal cultures
were isolated from P0 pups and neuronal cells isolated by incubation in a solution
containing 10 units of papain/ml, and cultured in DMEM with 25 mM HEPES
supplemented with 5% FCS, 15 mM KCl, x0.75 Penicillin/Streptovidin/glutamine
(Gibco, Paisley, UK) and serum extender (BD Biosciences, Oxford, UK).
Cell viability studies. The neuroprotective effects of α2 agonists were
assessed in vitro using either the MTT or the alamarblue cell viability assays. In
brief, RN were seeded at a density of 3 × 103 cells/well in a 96-well plate and
cultured for 24 h (37 °C, 5% CO2) before incubation with specified concentrations of
BMD prepared from a 24 mM stock solution in DMSO, Clo and Dex for 24 h. Cells
were insulted with predetermined (IC50) concentrations of CoCl2 or UV-B light for
24 h. Cell viability was assessed using MTT assay, where cells were treated with
0.5 mg/ml MTT in culture media for 2 h before dissolving the resulting formazan
crystals using DMSO (0.1 ml/well) and measuring absorbance (Safire microplate
reader) at 570 nm. For the alamarblue viability assay, 10 μl of alamarblue solution
was added per 100 μl DMEM and incubated for 1.5 h measuring absorbance (Safire
microplate reader) at 570nm. All experiments were carried out in triplicate.
Assessment of secreted MMP-9 activity by zymography. RNs
were cultured to 70–80% confluence before pretreatment with BMD and insulting
with 250 μM CoCl2 for 24 h. Conditioned media was collected in the presence of
protease cocktail inhibitors (Merck, Millipore, Nottingham, UK), and concentrated
using centrifugal filters with a MWCO of 10kDa. Total protein concentration was
determined using a BCA assay kit (Thermo Scientific, Rockford, IL, USA) according
to manufacturer’s instructions. Conditioned media containing 20 μg of protein per
sample was run on a 10% SDS gel containing 0.1% gelatin (Sigma) at 180 V for 1 h
rtp. SDS was removed by two 45 min washes in 2.5% PBS-Triton, followed by
incubation in developing buffer (Invitrogen, Paisley, UK) overnight at 37 °C. Gels
were stained with Coomassie blue to reveal clear bands indicating the presence of
secreted pro- and active MMP-9.82
Immunocytochemistry. Immunocytochemistry was performed to elucidate
mechanisms of α2 agonist-associated neuroprotection. RNs were seeded on glass
coverslips before pre-treating with BMD, Clo or Dex for 24 h and insulted with
250 μM CoCl2 or UV-B light (80 j/cm
2) for a further 24 h. Cells were fixed in 4%
paraformaldehyde before permeabilizing with 0.1% PBS-Triton and blocking with 3%
BSA. Cells were incubated overnight in either anti-P-Bad (Ser136), anti-sAPPα,
anti-APP or anti-Aβ with anti-α Tubulin (Cell Signalling Technology, Beverly, MA,
USA) to visualise cell structure. Antibodies were diluted 1:100 in 3% BSA, except
anti-α Tubulin (1:50) (Table 1). Fluorescence microscopy and analysis was
performed as described previously. All experiments were carried out in triplicate.
Experimental design. Sample size estimation for the OHT study was based
on the size of 'neuroprotective' effects of BMD in glaucoma patients in preserving
visual field in the LoGTs study.13 This effect was 90.9%, and based on a power of
0.85 and alpha of 5%, this provided a minimum number of four animals per group
per time point. OHT rats were randomly assigned in blocks of three to treatment with
either BMD or Clo (n= 5 at 3 weeks and n= 5 at 8 weeks), or vehicle (PBS,
n= 10). For the Aβ model, samples size was based on our previous published
results.4 Ex vivo analyses were planned with five rats per group, but owing to one
death and one atrophic retina, a final number of three to five rats per group were
used, as sample material was limited. Animals were randomly assigned in blocks of
three to treatment, as above. All in vitro experiments were carried out in triplicate.
Statistical analysis. Unless otherwise stated all statistical tests comprise a
one-way ANOVA with either Dunnett’s or Tukey’s post-tests, with Po0.05 taken as
statistical significance.
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